{"schema_version":"secwatch.filing_event.v1","accession":"0001274737-25-000061","form_type":"8-K","ticker":"XGN","cik":"0001274737","company_name":"EXAGEN INC.","filed_at":"2025-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.563318+00:00","generated_at":"2026-05-17T23:32:52.091676+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Exagen Q2 revenue $17.2M (+14% YoY); net loss widens to $4.4M; FY guidance $65-70M","bullets":["Revenue $17.2M, 14% YoY growth; AVISE CTD test volume +7% YoY, +14% QoQ; gross margin 60.4%.","Net loss $4.4M vs $3.0M in Q2 2024; operating loss $2.6M, roughly flat; adjusted EBITDA -$1.7M.","Cash $30.0M after $20.2M public offering and new credit facility; ASP $428, up $27 YoY.","FY 2025 revenue guidance $65M-$70M; expects positive adjusted EBITDA in Q4 at high end.","Appointed Dr. Michael Mahler as CSO; added Chas McKhann to board of directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001274737-25-000061","json":"https://secwatch.observer/filing/0001274737-25-000061.json","markdown":"https://secwatch.observer/filing/0001274737-25-000061.md","text":"https://secwatch.observer/filing/0001274737-25-000061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1274737/000127473725000061/0001274737-25-000061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1274737/000127473725000061/exdx-20250729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:32:52.091676+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}